At the ASCO 2019 annual meeting, Janice Mehnert discusses GITR as an emerging novel checkpoint in immunotherapy as well as sharing the findings from the recent study investigating the compound MK-4166 (NCT02132754) and considering the next steps in its clinical development.
1. What are the limitations of current immunotherapies in the treatment of solid tumours? (0:04)
2. What is the rationale for targeting glucocorticoid-induced tumour necrosis factor receptor (GITR)? (0:43)
3. What were the efficacy and safety findings of the recent study investigating MK-4166 as monotherapy or with pembrolizumab in patients with advanced solid tumours? (1:40)
4. What will be the next step in the clinical development of MK-4166? (2:39)
5. What other costimulatory receptors appear to be promising therapeutic targets? (3:23)
Speaker disclosure: Janice Mehnert has acted as a consultant for Merck & Co and participated in advisory boards for BMS, Reserit, Merck, Incyte and AstraZeneca.
Filmed at the American Society of Clinical Oncology (ASCO) 2019 Annual Meeting, Chicago, IL, USA.
Share this Video
Related Videos In Haematological Malignancies
Massimo Breccia, ASH 2022: Asciminib for patients with chronic myeloid leukaemia, the ASC4OPT study
The ASC4OPT study aims to potentially optimize dosing levels of asciminib in patients with chronic myeloid leukaemia in the chronic phase that have previously been treated with 2 lines of tyrosine kinase inhibitors. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the ASCEMBL findings, what we […]
Massimo Breccia, ASH 2022: The limitations of tyrosine kinase inhibitors in chronic myeloid leukaemia and approval status of asciminib
Tyrosine kinase inhibitors (TKIs) are the standard of care in the treatment of chronic myeloid leukaemia (CML). Asciminib is the first BCR::ABL1 inhibitor that functions by specifically targeting the ABL myristoyl pocket. In this touchONCOLOGY interview, we speak with Professor Massimo Breccia (University of Rome, Rome, Italy) to discuss the limitations of TKIs in the […]
Shaji Kumar, ASH 2022: Promising new agents enhancing the treatment of multiple myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses some promising new agents for the treatment of multiple myeloma, including immunotherapies like CAR-T cell therapies, as well as data from novel bispecific antibodies in the context of relapsed or refractory multiple myeloma. Abstract 158: Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!